A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT)

NCT03086564 PHASE1, PHASE2 COMPLETED

The effect of anti-tumor treatment is not satisfying in HBV-related hepatocellular carcinoma (HBV-HCC) for reasons that HBV-HCC carries highly heterogeneous antigens to facilitate cancer cells escaping from immune surveillance and constructs an immunosuppressive microenvironment. Correspondingly, dendritic cells activated by HBV antigen peptides and HepG2 cell protein lysate can efficiently present T cells with antigens of HCC to sensitize their antitumor properties meanwhile cyclophosphamide(CY) can effectively improve the microenvironment of immunity. Therefore, we put forward a new scientific therapy called "Activated Dendritic-cells Combined Cyclophosphamide" (ADCC) combining with TACE for patients with advanced hepatocellular carcinoma to prolong their survival time.

Details

Lead sponsor	Yuehua Huang
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	70
Start date	Mon May 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Oct 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hepatocellular Carcinoma

Interventions

• ADCC & TACE
• TACE

Countries

China